DE69435044D1 - Rapamycin - Konjugate und Antikörper - Google Patents

Rapamycin - Konjugate und Antikörper

Info

Publication number
DE69435044D1
DE69435044D1 DE69435044T DE69435044T DE69435044D1 DE 69435044 D1 DE69435044 D1 DE 69435044D1 DE 69435044 T DE69435044 T DE 69435044T DE 69435044 T DE69435044 T DE 69435044T DE 69435044 D1 DE69435044 D1 DE 69435044D1
Authority
DE
Germany
Prior art keywords
antibodies
rapamycin conjugates
rapamycin
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435044T
Other languages
English (en)
Other versions
DE69435044T2 (de
Inventor
Katherine L Molnar-Kimber
Craig E Caufield
Timothy D Ocain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE69435044D1 publication Critical patent/DE69435044D1/de
Application granted granted Critical
Publication of DE69435044T2 publication Critical patent/DE69435044T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
DE69435044T 1993-04-23 1994-04-22 Rapamycin - Konjugate und Antikörper Expired - Lifetime DE69435044T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5303093A 1993-04-23 1993-04-23
US53030 1993-04-23
US22420594A 1994-04-14 1994-04-14
US224205 1994-04-14

Publications (2)

Publication Number Publication Date
DE69435044D1 true DE69435044D1 (de) 2007-12-27
DE69435044T2 DE69435044T2 (de) 2008-09-18

Family

ID=26731364

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435044T Expired - Lifetime DE69435044T2 (de) 1993-04-23 1994-04-22 Rapamycin - Konjugate und Antikörper
DE69430060T Expired - Lifetime DE69430060T2 (de) 1993-04-23 1994-04-22 Antikörper von rapamycinen mit offenem ring

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69430060T Expired - Lifetime DE69430060T2 (de) 1993-04-23 1994-04-22 Antikörper von rapamycinen mit offenem ring

Country Status (8)

Country Link
US (2) US6328970B1 (de)
EP (2) EP0710110B1 (de)
JP (3) JPH08509499A (de)
AU (1) AU686629B2 (de)
CA (1) CA2161101A1 (de)
DE (2) DE69435044T2 (de)
ES (2) ES2176245T3 (de)
WO (1) WO1994025022A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US7078495B1 (en) * 1999-08-03 2006-07-18 Dade Behring Inc. Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
EP1212331B1 (de) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapaloge
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
DE60231868D1 (de) * 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CN101717410B (zh) * 2002-02-01 2015-04-29 阿里亚德医药股份有限公司 含磷化合物及其应用
AU2003243226A1 (en) * 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
EP2517730A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
ES2425167T3 (es) * 2004-03-10 2013-10-11 Seradyn, Inc. Inmunoensayos para everolimús
MXPA06011882A (es) * 2004-04-14 2006-12-14 Wyeth Corp Procedimiento para preparar 42-esteres de rapamicina y 32-esteres de fk 506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos.
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
BRPI0514206A (pt) * 2004-08-10 2008-06-03 Wyeth Corp composto, anticorpo, kit para monitorar a terapia com cci-779, e, métodos para detectar metabólitos de cci-779, e para produzir um metabólito sintético e um derivado de cci-779
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
AU2005319454B2 (en) 2004-12-20 2012-08-09 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
US7189582B2 (en) 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
RU2470668C2 (ru) * 2005-08-19 2012-12-27 Эндосайт, Инк. Конъюгаты лиганда с несколькими лекарственными средствами
CN102579467A (zh) 2005-11-14 2012-07-18 阿里亚德医药股份有限公司 雷帕霉素衍生物在治疗癌症中的用途
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2669415A1 (en) 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
WO2008065887A1 (fr) 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
ES2393135T3 (es) 2006-12-29 2012-12-18 Abbott Laboratories Ensayo mejorado para fármacos inmunosupresores
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
EP2118657B1 (de) 2006-12-29 2014-05-21 Abbott Laboratories Nichtdenaturierendes lysereagens zur verwendung mit einem capture-in-solution-immunoassay
CA2672972C (en) 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN103948937A (zh) * 2007-03-14 2014-07-30 恩多塞特公司 结合配体连接的微管溶素递药缀合物
JP2010523566A (ja) * 2007-04-05 2010-07-15 ワイス エルエルシー ワートマニン−ラパマイシンコンジュゲートおよびその使用
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
RU2523909C2 (ru) * 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2329816B1 (de) * 2009-11-26 2016-04-13 National Taiwan University Antikrebs-Wirkstoff aus Antrodia camphorata, Herstellungsverfahren und Verwendung dafür
JP6195846B2 (ja) 2012-01-27 2017-09-13 ノボ・ノルデイスク・エー／エス スライド目盛りを備える注射装置
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2014062697A2 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
JP6525971B2 (ja) 2013-06-11 2019-06-05 タカラ バイオ ユーエスエー， インコーポレイテッド タンパク質富化微細小胞、タンパク質富化微細小胞の作製方法及び使用方法
TW201511785A (zh) 2013-07-17 2015-04-01 Sanofi Sa 顯示器總成及施配裝置
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN105461738B (zh) * 2014-06-03 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
EP3310786B1 (de) * 2015-06-16 2021-03-03 Nanophagix LLC Chemisches konjugat für wirkstofffreisetzung und bildgebung, formulierungen und verfahren zur verwendung davon
US10456477B2 (en) * 2016-03-14 2019-10-29 Wisconsin Alumni Research Foundation Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
EP0201751A2 (de) * 1985-05-08 1986-11-20 Abbott Laboratories 4-Aminomethylfluoreszeinderivate zur Verwendung in Fluoreszenz-Polarisationsimmunotesten
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
EP0238801A1 (de) 1986-02-19 1987-09-30 Siemens Aktiengesellschaft Mehrpolige elektrische Steckverbindung
EP0283801A3 (de) 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
DE3886265T2 (de) 1987-06-05 1994-04-28 Fujisawa Pharmaceutical Co Anti-FR-900506-Stoffe-Antikörper und höchstempfindliches Enzym-Immunoassay-Verfahren.
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
JPH0633315B2 (ja) * 1988-01-25 1994-05-02 ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング ハプテン誘導体、その製法、ハプテン／蛋白質―接合体、その製法、抗体の製法及びイムノアッセイの標識酵素
AU4958590A (en) 1988-12-05 1990-07-10 Trustees Of Columbia University In The City Of New York, The Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
CA2045673A1 (en) 1989-01-30 1990-07-31 Stefan Gavojdea Detection of antibodies in body fluids for diagnostic testing
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
ES2084069T3 (es) 1990-08-15 1996-05-01 Abbott Lab Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina.
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
DE69121844T2 (de) 1990-11-20 1997-01-23 Behringwerke Ag Immunotest für Cyclosporin
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5225543A (en) 1991-03-28 1993-07-06 American Cyanamid Company Receptors method for purification of g protein-linked
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
IL101353A0 (en) 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
WO1993019752A1 (en) * 1992-04-07 1993-10-14 Dana-Farber Cancer Institute, Inc. Inhibition of p70 s6 kinase
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
DK0734389T3 (da) 1993-12-17 2000-08-21 Novartis Ag Rapamycinderivater, som er anvendelige som immunosuppressive midler
PL184731B1 (pl) 1995-06-09 2002-12-31 Novartis Ag Pochodne rapamycyny, zastosowanie pochodnych rapamycyny i kompozycja farmaceutyczna

Also Published As

Publication number Publication date
AU686629B2 (en) 1998-02-12
EP1181938A3 (de) 2002-03-20
US6328970B1 (en) 2001-12-11
EP0710110A1 (de) 1996-05-08
ES2176245T3 (es) 2002-12-01
DE69430060D1 (de) 2002-04-11
JP2004168782A (ja) 2004-06-17
EP0710110B1 (de) 2002-03-06
US20010010920A1 (en) 2001-08-02
DE69435044T2 (de) 2008-09-18
EP1181938A2 (de) 2002-02-27
JP2004149542A (ja) 2004-05-27
WO1994025022A1 (en) 1994-11-10
DE69430060T2 (de) 2002-11-07
CA2161101A1 (en) 1994-11-10
US6541612B2 (en) 2003-04-01
AU6772094A (en) 1994-11-21
ES2295093T3 (es) 2008-04-16
EP0710110A4 (de) 1997-06-18
EP1181938B1 (de) 2007-11-14
JPH08509499A (ja) 1996-10-08

Similar Documents

Publication Publication Date Title
DE69435044D1 (de) Rapamycin - Konjugate und Antikörper
DK145493D0 (da) Antistof
DE69532671D1 (de) Endoprothesen und stents
DE69425782D1 (de) Hyterosalpingographie und selektive Salpingographie
DE69624356D1 (de) Drehregner und standfuss
DE69502489D1 (de) Haftkleber und artikel
NO962346D0 (no) Humaniserte antistoffer og anvendelser derav
DK0700353T3 (da) Selvlukkende arrangement
AU6711994A (en) Rapamycin conjugates and antibodies
DE69622748D1 (de) Längliche ptfe-elemente und daraus hergestellte artikel
DE69527045D1 (de) Tetrahydrofurane und tetrahydropyrane
DE69623008T2 (de) Seismometer und dergleichen
DE69418569D1 (de) Resistmateralien und entsprechende Verfahren
DE69614491T2 (de) 5HT1Dalpha und 5HT2A Ligande
DE69417452T2 (de) Buchklammer und lesezeichen
HU9501990D0 (en) Rapamycin conjugates and antibodies
GB9419256D0 (en) Antibody and conjugates
NO951061D0 (no) Antistoffkonjugater med forbedrede egenskaper
KR940027776U (ko) 개방범위 한정장치
KR940023380U (ko) 댐퍼장치
KR950002524U (ko) 댐퍼장치
KR950000146U (ko) 재떨이
KR950000148U (ko) 재떨이
KR950013041U (ko) 재털이
DE9307615U1 (de) Aschenbecher

Legal Events

Date Code Title Description
8364 No opposition during term of opposition